• HeartBeam shifted strategy to license its 3D ambulatory ECG signal platform to established partners, moving away from direct medical device sales.
• Reorganization targets broader global reach, higher capital efficiency, streamlined execution, lower costs.
• Plans to expand beyond arrhythmia assessment into heart attack detection, prioritizing clinical evidence to support the indication.
• Commercial approach centers on tailoring the platform to multiple channels with existing distribution, including health systems, OEMs, national health systems.
• More strategy detail slated for the second-quarter 2026 conference call in August.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartbeam Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606241605BIZWIRE_USPR_____20260624_BW011757) on June 24, 2026, and is solely responsible for the information contained therein.